A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice

Romiplostim has maintained long‐term platelet counts in patients with immune thrombocytopenia (ITP) for up to 5 yr in clinical studies. This prospective observational study aimed to describe romiplostim utilisation and outcomes in European clinical practice.

[1]  J. Viallard,et al.  Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study , 2016, British journal of haematology.

[2]  Y. Tomiyama,et al.  Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia , 2015, Annals of Hematology.

[3]  J. Wasser,et al.  Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim , 2015, International Journal of Hematology.

[4]  M. Steurer,et al.  Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity , 2015, Acta Haematologica.

[5]  N. Mohandas,et al.  Jekyll and Hyde: the role of heme oxygenase-1 in erythroid biology , 2015, Haematologica.

[6]  P. Galan,et al.  Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia , 2014, American journal of hematology.

[7]  B. Chong,et al.  Final Results from a Phase 4 Open-Label 3-Year Study Evaluating Changes in Bone Marrow (Bm) Morphology in Adult Immune Thrombocytopenia (ITP) Patients (Pts) Receiving the Thrombopoietin Mimetic Romiplostim , 2014 .

[8]  F. Roudot-thoraval,et al.  The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study , 2014, British journal of haematology.

[9]  D. Cines,et al.  Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials , 2013, European journal of haematology.

[10]  J. Bussel,et al.  Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy , 2013, British journal of haematology.

[11]  J. Bussel,et al.  Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. , 2013, Blood.

[12]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[13]  B. Chong,et al.  Romiplostim or standard of care in patients with immune thrombocytopenia. , 2010, The New England journal of medicine.

[14]  I. Pabinger,et al.  Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate , 2010, Annals of Hematology.

[15]  A. Newland,et al.  Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside , 2010, British journal of haematology.

[16]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[17]  F. Mowat,et al.  Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database , 2009, British journal of haematology.

[18]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[19]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[20]  P. Rebulla,et al.  Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies , 2003, Transfusion.